XXXX therapy in late-life major @entity308 in males.

@entity1 @entity251 @entity308 @entity263 @entity134 @entity11335 @entity1486
BACKGROUND: @entity308 associated with aging in males may improve with anabolic/androgenic @entity134 therapy. The efficacy and safety of @entity251 therapy in the treatment of @entity308 in elderly hypogonadal males is inconclusive. The following study identifies a subgroup of elderly depressed males who may benefit from @entity251 therapy. METHOD: @entity1 included 16 elderly eugonadal males with @entity308 (DSM-IV criteria) and a Hamilton Rating Scale for @entity308 (HAM-D) score > 18. Following a single-blind 2-week placebo lead-in, @entity1 were randomly assigned to treatment with either a physiologic dose of @entity11335 (TC), 100 mg/week, or supraphysiologic dose of 200 mg/week IM for 6 weeks. Psychometric testing was carried out at entry into the study, at the TC injection baseline, and every 2 weeks thereafter. Tests included an objective measurement, the HAM-D, and the Buss-Durkee Hostility Inventory. RESULTS: One @entity1 meeting inclusion criteria responded during the placebo lead-in; thus, 15 @entity1 were randomly assigned to treatment (100 mg/week, N = 8; 200 mg/week, N = 7). There was a 42% decrease in the mean HAM-D scores from 20.1 to 11.9 (p <.0001). However, the majority of the change was due to improvement in the 10 late-onset (< or = 45 years old) @entity308 @entity1 , whose mean HAM-D score decreased from 19.8 to 9.3 (53%), versus the 5 early-onset @entity308 @entity1 , whose mean HAM-D score decreased from 20.8 to 17.0 (18%) (p =.0110). The TC dose did not affect the response. Similar HAM-D decreases of 43% and 41% occurred for the respective 100- and 200-mg/week doses. The HAM-D responder analysis found that none of 5 early-onset @entity1 had HAM-D response, whereas 6 (60%) of 10 late-onset @entity1 responded (p =.025). Similarly, none of the early-onset @entity1 experienced a remission whereas 5 (50%) of the late-onset @entity1 were categorized as remitters (p =.053). Correlations between the peak and mean total @entity251 concentrations and HAM-D change scores suggested that only minimal TC doses were required to produce an antidepressant effect. CONCLUSION: These data suggest that @entity251 therapy would best be limited to @entity1 with late-onset @entity308 . The findings suggest that short-term therapy with TC is safe. Long-term treatment safety is unknown. Psychiatrists using @entity251 therapy should ascertain that @entity1 have been recently valuated for @entity263 . If @entity251 therapy is initiated, serial serum @entity1486 sampling should be used for monitoring @entity1 ' prostate status.
